Clinical Trials Logo

Geographic Atrophy clinical trials

View clinical trials related to Geographic Atrophy.

Filter by:

NCT ID: NCT05893537 Recruiting - Clinical trials for Age-Related Macular Degeneration

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Start date: June 16, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.

NCT ID: NCT05891275 Completed - Geographic Atrophy Clinical Trials

Patients With Geographic Atrophy and Their Patient Journey in the United States (US)

Start date: May 31, 2023
Phase:
Study type: Observational

To quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).

NCT ID: NCT05839041 Recruiting - Clinical trials for Macular Degeneration

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

SIGLEC
Start date: May 2, 2023
Phase: Phase 2
Study type: Interventional

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.

NCT ID: NCT05811351 Recruiting - Geographic Atrophy Clinical Trials

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Start date: March 6, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

NCT ID: NCT05797896 Recruiting - Clinical trials for Macular Degeneration

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

i-GAIN
Start date: February 7, 2023
Phase:
Study type: Observational

An observational study to investigate the natural history and evaluate biomarkers of participants with geographic atrophy secondary to age-related macular degeneration

NCT ID: NCT05626114 Recruiting - Geographic Atrophy Clinical Trials

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Start date: March 24, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated.

NCT ID: NCT05536297 Active, not recruiting - Clinical trials for Macular Degeneration

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Start date: September 26, 2022
Phase: Phase 3
Study type: Interventional

Patients who completed Study ISEE2008 (GATHER2) and consent to participate will be administered monthly avacincaptad pegol 2 mg.

NCT ID: NCT05481827 Enrolling by invitation - Clinical trials for Age Related Macular Degeneration (AMD)

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

ORACLE
Start date: July 12, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.

NCT ID: NCT05447650 Recruiting - Clinical trials for Age-Related Macular Degeneration

Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)

i-SIGHT
Start date: April 12, 2022
Phase: N/A
Study type: Interventional

Evaluate the safety and efficacy of transpalpebral microcurrent stimulation (MCS) therapy for patients with nonexudative (dry) age-related macular degeneration (AMD).

NCT ID: NCT05438732 Recruiting - Clinical trials for Age-Related Macular Degeneration

Multicenter Clinical Study of the SING-IMT in Patients With Late-stage AMD

CONCERTO
Start date: June 16, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).